Context Therapeutics is trading 6.02% down at $0.47 after no confirmed company-specific catalyst was identified for August 24, 2026.
- The latest investor-relations release was dated August 5, 2026; available filings show no newer material announcement.
- Broader sentiment is modestly negative, with Nasdaq futures down 0.50% and elevated Treasury yields pressuring risk-sensitive assets, though the backdrop does not clearly explain this move.